Navigation Links
Carmex Takes Moisture to the Next Level With New Carmex Moisture Plus(TM)
Date:10/28/2008

Ultra-Hydrating Lip Balm with a Slant-Tipped Applicator Now Available

Exclusively at Walgreens and Walgreens.com

MILWAUKEE, Oct. 28 /PRNewswire/ -- Carma Laboratories, Inc., the makers of Carmex(R) lip balm products, today announced the arrival of new Carmex Moisture Plus(TM) ultra-hydrating lip balm which provides intense moisturizing protection with vitamin E, aloe, shea butter and avocado butter. Available exclusively at Walgreens and Walgreens.com, the new premium lip balm is packaged in a sleek applicator and provides a hint of gloss as well as an SPF 15 rating. The suggested retail price for Carmex Moisture Plus is $2.99.

"Now women don't have to choose fashion over function because Carmex Moisture Plus combines both," said Paul Woelbing, president of Carma Laboratories. "Carmex Moisture Plus provides a powerful, moisturizing lip balm with a sophisticated slant-tipped applicator."

Carmex Moisture Plus joins the popular Carmex family of products. Carmex is available in a variety of forms like jar, tube and stick; a variety of flavors like cherry, strawberry and mint; and some with sun protection. For 10 years running, Carmex has been the most pharmacist-recommended lip balm, ranking #1 in a national survey of over-the-counter lip balm products by Pharmacy Times magazine.

About CARMEX and Carma Laboratories, Inc.

For over 70 years, Milwaukee-based Carma Laboratories has manufactured Carmex brand lip balm. Carmex has been named the #1 pharmacist-recommended lip balm by Pharmacy Times magazine for the past ten years. Carmex products are available at U.S. retailers, including Walmart, Walgreens, Target, CVS, Kroger, and Rite Aid, and online at Walgreens, CVS, Drugstore.com, Longs, Sam's Club and REI. For more information, contact Carma Laboratories at (414) 421-7707 or visit http://www.mycarmex.com.


'/>"/>
SOURCE Carma Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Agency Takes Adverse Decision to Biopures Product Registration in South Africa
2. Video: The Cigarette Is Dead Social Movement Takes Aim at Deadly Icon
3. Golden Meditech Increases Stakes in Cordlife, Largest Cord Blood Bank Operator in Southeast Asia
4. Mike Bridges Takes Home Four Gold Medals at IPF Masters World Powerlifting Championships; Says NutraCeas RiSolubles(R) is an Essential Part of his Training Regimen
5. My1Stop.com Takes Commercial Printing Global with International Shipping of Custom Printed Products
6. New Method of Therapy Takes Patients Out of the Clinic and Into the Park
7. Economic Crisis Takes Toll on Emotional Health
8. DuPages Only Provider of Head Start Takes Aim at Childhood Obesity in Minorities
9. My1Stop.com Takes Top Honors from Webawards for Best Publishing Website Of 2008
10. InsureMyTrip.coms Expert Customer Care Team Takes the Guesswork Out of Buying Travel Insurance
11. Craig W. Philips Takes Helm at CTI
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10